Skip to main content
main-content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

World Journal of Surgical Oncology 1/2012

Correlation between promoter methylation of p14 ARF , TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma

Zeitschrift:
World Journal of Surgical Oncology > Ausgabe 1/2012
Autoren:
Liu Xiaofang, Tang Kun, Yu Shaoping, Wang Zaiqiu, Su Hailong
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-10-5) contains supplementary material, which is available to authorized users.

Competing interests

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Authors' contributions

LXF proposed the study and wrote the first draft of the manuscript. TK analyzed the data. All authors contributed to the design and interpretation of the study and to further drafts. LXF is the guarantor. All authors read and approved the final manuscript'

Abstract

Background

To study the methylation status of genes that play a role in the p53-Bax mitochondrial apoptosis pathway and its clinical significance in cholangiocarcinoma.

Patients and Methods

Out of 36 cases cholangiocarcinoma patients from April 2000 to May 2005 were collected.Promoter hypermethylation of DAPK, p14 ARF , and ASC were detected by methylation-specific PCR on cholangiocarcinoma and normal adjacent tissues samples. Mutation of the p53 gene was examined by automated sequencing. Correlation between methylation of these genes and/or p53 mutation status with clinical characteristics of patients was investigated by statistical analysis.

Results

We found 66.7% of 36 cholangiocarcinoma patients had methylation of at least one of the tumor suppressor genes analyzed. p53 gene mutation was found in 22 of 36 patients (61.1%). Combined p53 mutation and DAPK, p14 ARF , and/or ASC methylation was detected in 14 cases (38.9%). There were statistically significant differences in the extent of pathologic biology, differentiation, and invasion between patients with combined p53 mutation and DAPK, p14 ARF , and/or ASC methylation compared to those without (P < 0.05). The survival rate of patients with combined DAPK, p14 ARF , and ASC methylation and p53 mutation was poorer than other patients (P < 0.05).

Conclusion

Our study indicates that methylation of DAPK, p14 ARF , and ASC in cholangiocarcinoma is a common event. Furthermore, p53 mutation combined with DAPK, p14 ARF , and/or ASC methylation correlates with malignancy and poor prognosis.
Zusatzmaterial
Authors’ original file for figure 1
12957_2011_937_MOESM1_ESM.doc
Authors’ original file for figure 2
12957_2011_937_MOESM2_ESM.pdf
Authors’ original file for figure 3
12957_2011_937_MOESM3_ESM.pdf
Authors’ original file for figure 4
12957_2011_937_MOESM4_ESM.pdf
Authors’ original file for figure 5
12957_2011_937_MOESM5_ESM.doc
Authors’ original file for figure 6
12957_2011_937_MOESM6_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

World Journal of Surgical Oncology 1/2012 Zur Ausgabe

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise